The future of polymer therapeutics

Ruth Duncan offers her perspective of the challenges and opportunities for the polymer therapeutics community.  She discusses recent clinical successes and failures and offers valuable suggestions which could improve translation of products from the lab to the clinic.  Key considerations include (amongst others) appropriate selection of polymer and drug for a specific application, sufficient materials characterization (not just biological analysis), clinically relevant preclinical models and improved clinical trial design.

Polymer therapeutics: Top 10 selling pharmaceuticals — What next?, R.Duncan, Journal of Controlled Release, http://dx.doi.org/10.1016/j.jconrel.2014.05.001

http://www.sciencedirect.com/science/article/pii/S0168365914002922